International Award

Prix Galien International Award

 

The Prix Galien International Award is organized every second year. Candidates for the international prize have already been awarded a Prix Galien at a national awards event in the two years prior.

Committee

SIRTURO (Bédaquiline, Janssen)

KEYTRUDA (Pembrolizumab, MSD)

ORPHACOL (CTRS)

Pr Thomas BAUMERT, a novel target for antiviral therapy in hepatitis C

Institute of Physiology and Pathology of Hearing, National Network of Teleaudiology

Ivacaftor (Kalydeco, Vertex Pharmaceuticals)

Bocéprevir (Victrelis, MSD)

Télaprévir (Incivo, Janssen)

Ustekinumab (Stelara, Janssen)

Rivaroxaban (Xarelto, Bayer Schering)

Romiplostim (NPlate, Amgen)

Gardasil (Sanofi-Pasteur MSD)

Bortezomid (Velcade, Janssen-Cilag)

Enfuvirtide (Fuzéon, Produits Roche)

Imatinib (Glivec-Gleevec, Novartis)

Infliximab (Remicade, Schering-Plough)

Inhibiteurs des antiprotéases : indinavir (Crixivan, MSD)

Ritonavir (Norvir, Abbott)

Saquinavir (Invirase, F. Hoffmann – La Roche)

Rispéridone (Risperdal, Janssen-Cilag)

Hepatitus A vaccine (Havrix, SmithKline-Beecham)

Filgrastim (Neupogen, Roche-Amgen)

Ondansétron (Zophren, Glaxo-Wellcome)

From national and world leaders to shining lights within the pharmaceutical industries, many have offered praise for the Prix Galien.